Edition:
United States

CytRx Corp (CYTR.PH)

CYTR.PH on Philadelphia Stock Exchange

0.81USD
26 Apr 2017
Change (% chg)

-- (--)
Prev Close
$0.81
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,633
52-wk High
$3.49
52-wk Low
$0.37

Select another date:

Wed, Apr 19 2017

BRIEF-Cytrx says FDA agreement on regulatory pathway for Aldoxorubicin

* Cytrx announces FDA agreement on regulatory pathway to approval for Aldoxorubicin in soft tissue sarcomas

BRIEF-Cytrx reports statistically significant updated results from pivotal phase 3 trial of aldoxorubicin in patients with second-line soft tissue sarcomas

* Cytrx-Reports statistically significant updated results from pivotal phase 3 trial of aldoxorubicin in patients with second-line soft tissue sarcomas

BRIEF-Cytrx presents positive interim results from on-going clinical trial

* Cytrx says dose-limiting toxicities were not observed in either cohort, and no clinically significant cardiac toxicities were seen

BRIEF-Cytrx Q3 loss $0.13/shr

* Cytrx Corp - during Q3, embarked on a plan to reduce spending until additional results from Aldoxorubicin phase 3 STS clinical trial are available

Select another date:

More From Around the Web